These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35038987)

  • 1. A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different Italian regions.
    Kondili LA; Andreoni M; Alberti A; Lobello S; Babudieri S; De Michina A; Merolla R; Marrocco W; Craxì A
    BMC Infect Dis; 2022 Jan; 22(1):58. PubMed ID: 35038987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression.
    Kondili LA; Andreoni M; Alberti A; Lobello S; Babudieri S; Roscini AS; Merolla R; Marrocco W; Craxì A
    Epidemics; 2021 Mar; 34():100442. PubMed ID: 33607538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of hepatitis C virus estimates of undiagnosed individuals in different Italian regions: a mathematical modelling approach by route of transmission and fibrosis progression with results up to January 2021.
    Kondili LA; Andreoni M; Aghemo A; Mastroianni CM; Merolla R; Gallinaro V; Craxì A
    New Microbiol; 2022 Dec; 45(4):249-259. PubMed ID: 36066213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.
    Smith DJ; Combellick J; Jordan AE; Hagan H
    Int J Drug Policy; 2015 Oct; 26(10):911-21. PubMed ID: 26298331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
    Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of new direct-acting antiviral therapy on the prevalence and undiagnosed proportion of chronic hepatitis C infection.
    Forouzannia F; Hamadeh A; Passos-Castilho AM; Erman A; Yu A; Feng Z; Janjua NZ; Sander B; Greenaway C; Wong WWL
    Liver Int; 2024 Jun; 44(6):1383-1395. PubMed ID: 38445848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?
    Kondili LA; Robbins S; Blach S; Gamkrelidze I; Zignego AL; Brunetto MR; Raimondo G; Taliani G; Iannone A; Russo FP; Santantonio TA; Zuin M; Chessa L; Blanc P; Puoti M; Vinci M; Erne EM; Strazzabosco M; Massari M; Lampertico P; Rumi MG; Federico A; Orlandini A; Ciancio A; Borgia G; Andreone P; Caporaso N; Persico M; Ieluzzi D; Madonia S; Gori A; Gasbarrini A; Coppola C; Brancaccio G; Andriulli A; Quaranta MG; Montilla S; Razavi H; Melazzini M; Vella S; Craxì A;
    Liver Int; 2018 Dec; 38(12):2190-2198. PubMed ID: 29900654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries.
    Obach D; Yazdanpanah Y; Esmat G; Avihingsanon A; Dewedar S; Durier N; Attia A; Anwar WA; Cousien A; Tangkijvanich P; Eholié SP; Doss W; Mostafa A; Fontanet A; Mohamed MK; Deuffic-Burban S
    Hepatology; 2015 Jul; 62(1):31-9. PubMed ID: 25581111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients with chronic hepatitis C infection in Lombardia: a report by the Lombardia Hepatitis Network.
    Aghemo A; Bruno R; Colombo M; Medagli M; Puoti M; Rizzardini G; Fagiuoli S;
    Eur Rev Med Pharmacol Sci; 2016 Dec; 20(1 Suppl):17-19. PubMed ID: 28083863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters.
    Parczewski M; Kordek J; Janczewska E; Pisula A; Łojewski W; Socha Ł; Wawrzynowicz-Syczewska M; Bociąga-Jasik M; Szymczak A; Cielniak I; Siwak E; Mularska E; Aksak-Wąs B; Urbańska A; Lübke N
    Clin Microbiol Infect; 2019 Apr; 25(4):513.e1-513.e6. PubMed ID: 29981869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.
    Ruggeri M; Coretti S; Romano F; Kondili LA; Vella S; Cicchetti A
    Value Health; 2018 Jul; 21(7):783-791. PubMed ID: 30005750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
    Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
    Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression.
    Thein HH; Yi Q; Dore GJ; Krahn MD
    Hepatology; 2008 Aug; 48(2):418-31. PubMed ID: 18563841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global prevalence of hepatitis C virus in children in 2018: a modelling study.
    Schmelzer J; Dugan E; Blach S; Coleman S; Cai Z; DePaola M; Estes C; Gamkrelidze I; Jerabek K; Ma S; Montoya S; Razavi-Shearer D; Razavi-Shearer K; Robbins-Scott S; Razavi H; El Sayed MH
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):374-392. PubMed ID: 31954439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
    Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
    S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype Distribution and Characteristics of Chronic Hepatitis C Infection in Estonia, Latvia, Lithuania, and Ukraine: The RESPOND-C Study.
    Jančorienė L; Rozentāle B; Tolmane I; Jēruma A; Salupere R; Buivydienė A; Valantinas J; Kupčinskas L; Šumskienė J; Čiupkevičienė E; Ambrozaitis A; Golubovska O; Moroz L; Flisiak R; Bondar B
    Medicina (Kaunas); 2023 Aug; 59(9):. PubMed ID: 37763696
    [No Abstract]   [Full Text] [Related]  

  • 18. Forecasting the long-term impact of COVID-19 on hepatitis C elimination plans in Italy: A mathematical modelling approach.
    Kondili LA; Andreoni M; Aghemo A; Mastroianni CM; Merolla R; Gallinaro V; D'Offizi G; Craxì A
    Liver Int; 2023 Dec; 43(12):2615-2624. PubMed ID: 37735959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
    PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hepatitis C in a psychiatric setting: A forgotten reservoir?].
    Rolland B; Bailly F; Cutarella C; Drevon O; Carrieri P; Darque A; Hallouche N; Maptue N; Pol S; Llorca PM; Lang JP
    Encephale; 2021 Apr; 47(2):181-184. PubMed ID: 32473777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.